All > Vermont > Spokane

Inotuzumab Ozogamicin for Refractory B Acute Lymphoblastic Leukemia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Refractory B Acute Lymphoblastic Leukemia+3 MoreInotuzumab Ozogamicin - Biological
Eligibility
1 - 21
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing inotuzumab ozogamicin to see if it can help patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment.

Eligible Conditions
  • Refractory B Acute Lymphoblastic Leukemia
  • B Lymphoblastic Lymphoma
  • Refractory B-Cell Lymphoblastic Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia (ALL)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Venetoclax
1
Inotuzumab ozogamicin
1
Everolimus

Study Objectives

1 Primary · 11 Secondary · Reporting Duration: Up to 5 years

Year 5
Changes in peripheral blood absolute B cell numbers and maturation of developing B cell populations with inotuzumab ozogamicin therapy (Cohorts 1 and 2)
Intracellular signaling pathways in leukemic blasts treated with inotuzumab ozogamicin (Cohorts 1 and 2)
Baseline, post Cycle 1, and at time of relapse
Change in CD22 site density (Cohorts 1 and 2)
Changes in CD22 surface expression (Cohorts 1 and 2)
Baseline, post-Cycle 1, and at time of relapse
Leukemic blast CD22 splice variants (Cohorts 1 and 2)
Cycles 1 and 2
Immunogenicity (Cohort 1)
Day 28
Pharmacokinetic (PK) parameters, i.e., inotuzumab ozogamicin trough levels (Cohort 1)
Day 28
Incidence of dose-limiting toxicities at recommended phase II dose (RP2D) (Cohort 1)
Year 3
Event free survival (EFS) (Cohort 1)
Year 3
Overall survival (Cohort 1)
Overall survival (OS) (Cohort 1)
Year 1
Incidence of adverse events of sinusoidal obstruction syndrome (SOS) of liver (Cohort 1 and 2)
Month 12
Incidence of SOS in patients who receive prophylaxis with ursodeoxycholic acid (UDCA) during inotuzumab ozogamicin therapy (Cohorts 1 and 2)
Serum levels of candidate SOS biomarkers Ang2 and L ficolin (Cohorts 1 and 2)
Up to 2 cycles
Level of MRD by next-generation high-throughput sequencing (HTS) techniques (Cohorts 1 and 2)
Level of minimal residual disease (MRD) assessed in bone marrow by flow cytometry (Cohort 1 and 2)
Day 42
Morphologic response (CR/CRi) (Cohort 2)
Up to 28 days
Morphologic response (complete response [CR]+ incomplete hematologic recovery [CRi]) following one cycle of treatment with inotuzumab ozogamicin (Cohort 1)
Up to 3 years
Duration of CR, CRi (Cohort 1)
Up to 5 years
Interaction between CAR- T therapy and inotuzumab ozogamicin (Cohorts 1 and 2)
Up to 56 days
Morphologic response (CR + CRi) following 2 cycles of inotuzumab ozogamicin therapy (Cohort1)
Day 42
Incidence of dose-limiting toxicities at the selected dose level of inotuzumab ozogamicin in combination with the augmented modified Berlin-Frankfurt-Munster (mBFM) consolidation chemotherapy (Cohort 2)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Venetoclax
1
Inotuzumab ozogamicin
1
Everolimus

Side Effects for

Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2
50%Fatigue
42%Constipation
42%Nausea
33%Vomiting
33%Thrombocytopenia
25%Aspartate aminotransferase increased
17%Neutropenia
17%Decreased appetite
17%Headache
8%Presyncope
8%Wheezing
8%Encephalopathy
8%Central nervous system neoplasm
8%Pain
8%Lymph node pain
8%Splenomegaly
8%Sinusitis
8%Odynophagia
8%Catheter site erythema
8%Insomnia
8%Disease progression
8%Septic shock
8%Pyrexia
8%Oropharyngeal pain
8%Rhinorrhoea
8%Pruritus
8%Rash
8%Hypoaesthesia
8%Weight decreased
8%Tremor
8%Dyspnoea exertional
8%Skin exfoliation
8%Hyperkeratosis
8%Influenza
8%Alanine aminotransferase increased
8%Bacteraemia
8%Blood creatinine increased
8%Anaemia
8%Conjunctival haemorrhage
8%Asthenia
8%Tonsillar hypertrophy
This histogram enumerates side effects from a completed 2016 Phase 2 trial (NCT01363297) in the Phase 1 - Dose-Finding: IV Inotuzumab Ozogamicin 1.6 mg/m^2 ARM group. Side effects include: Fatigue with 50%, Constipation with 42%, Nausea with 42%, Vomiting with 33%, Thrombocytopenia with 33%.

Trial Design

2 Treatment Groups

Cohort II (inotuzumab ozogamicin, mBFM chemotherapy)
1 of 2
Cohort I (inotuzumab ozogamicin)
1 of 2

Experimental Treatment

80 Total Participants · 2 Treatment Groups

Primary Treatment: Inotuzumab Ozogamicin · No Placebo Group · Phase 2

Cohort II (inotuzumab ozogamicin, mBFM chemotherapy)Experimental Group · 13 Interventions: Diagnostic Imaging, Biospecimen Collection, Vincristine, Pegaspargase, Bone Marrow Aspiration and Biopsy, Calaspargase Pegol-mknl, Cyclophosphamide, Lumbar Puncture, Methotrexate, Leucovorin Calcium, Cytarabine, Mercaptopurine, Inotuzumab Ozogamicin · Intervention Types: Procedure, Procedure, Drug, Drug, Procedure, Drug, Drug, Procedure, Drug, Drug, Drug, Drug, Biological
Cohort I (inotuzumab ozogamicin)
Biological
Experimental Group · 1 Intervention: Inotuzumab Ozogamicin · Intervention Types: Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 1
~670
Vincristine
FDA approved
Asparaginase Escherichia coli
FDA approved
Calaspargase Pegol-mknl
2008
Completed Phase 3
~170
Cyclophosphamide
FDA approved
Lumbar Puncture
2006
Completed Phase 2
~210
Methotrexate
FDA approved
Calcium
Not yet FDA approved
Cytarabine
FDA approved
Mercaptopurine
FDA approved
Inotuzumab ozogamicin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years

Who is running the clinical trial?

Children's Oncology GroupLead Sponsor
448 Previous Clinical Trials
236,430 Total Patients Enrolled
1 Trials studying Refractory B Acute Lymphoblastic Leukemia
38 Patients Enrolled for Refractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)NIH
13,073 Previous Clinical Trials
41,138,828 Total Patients Enrolled
10 Trials studying Refractory B Acute Lymphoblastic Leukemia
610 Patients Enrolled for Refractory B Acute Lymphoblastic Leukemia
Maureen M O'BrienPrincipal InvestigatorChildren's Oncology Group

Eligibility Criteria

Age 1 - 21 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Leukemic blasts must show evidence of CD22 on the surface when tested using flow cytometry with a bone marrow aspirate sample, preferably with PE as the fluorophore.
Your age must be between one and 22 years at the time of enrollment.
You have been diagnosed with either B-ALL or B lymphoblastic lymphoma (B-LL) and your bone marrow blast count is at least 5%
Individuals with a prior diagnosis of B-LL and an M2 or M3 marrow at the time of enrollment are eligible for this study.
Patients with ALL or B-LL displaying M2 morphology must have a local assessment demonstrating at least 5% blasts through flow cytometry, FISH testing or another molecular approach.
You have had more than one relapse.
You have a primary refractory disease with two or more prior induction attempts.
You have experienced a relapse that was not responsive to one or more re-induction attempts.
For Cohort 1, there must not have been a relapse after hematopoietic stem cell transplantation.
If a bone marrow aspirate sample is inadequate or not feasible due to patient's clinical status, flow cytometry of peripheral blood specimen may be substituted if the circulating blasts are 1,000/uL; alternatively, CD22 expression can be determined from an immunohistochemistry analysis of a bone marrow biopsy.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top